GTx posts positive results in muscle drug trial; Amylin axes 60 staffers, including researchers;

 @FierceBiotech: Expert panel unanimously backs new 'morning after' pill. Report | Follow @FierceBiotech

 @JohnCFierce: Boehringer should have folded its flibanserin tent before letting an FDA panel unanimously reject it. Chances of approval: zero. | Follow @JohnCFierce

> GTx says its clinical trial of the muscle drug Ostarine delivered positive data in a study evaluating the drug's ability to improve lean body mass and muscle strength in post-menopausal women. An FDA meeting is scheduled later in the summer to review the late-stage study program for the therapy, which is partnered with Merck. Story

> San Diego-based Amylin Pharmaceuticals has axed about 60 staffers in a bid to become more efficient. The layoffs account for four percent of its workforce. A company official says that layoffs occurred in the R&D section of the company, which will help push the company to look outside its ranks for new discoveries. Report

> Dyax is gaining $5 million upfront and up to $100 million in milestones from a development and commercialization pact it has struck with Defiante Farmaceutica S.A. of Portugal on DX-88, a drug for HAE. Report

> The bioinformatics company Symyx Technologies has rejected a $200 million buyout offer from Certara, saying the bid isn't as good as the $183 million deal it has in place with Accelrys. Report

> Japan's Sosei Group has reached an agreement to acquire Activus Pharma, Activus' core technologies in drug formulation using nano-particle processing "will form the basis of Sosei's new platform technology." Sosei release

> A stem cell therapy being advanced by Gamida and Teva for blood cancers has been fast-tracked by the FDA. Story

And Finally... Obese people without metabolic risk factors for diabetes and heart disease, such as high blood pressure and cholesterol, do not have the elevated cardiovascular risk typical of obesity. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.